10-K: PDS Biotech Advances Cancer Therapies, Reports Strong Trial Data

PDS Biotechnology Corporation's 2025 annual report highlights significant progress in its oncology pipeline with promising clinical trial results for PDS0101 and PDS01ADC, despite ongoing financial losses and a going concern warning.

Summary

• PDS Biotechnology Corporation is a clinical-stage immunotherapy company developing targeted cancer and infectious disease immunotherapies based on its Versamune T cell activator and PDS01ADC platforms.
• The company reported a net loss of $34.5 million for the year ended December 31, 2025, an improvement from $37.6 million in 2024.
• Accumulated deficit reached $216.6 million as of December 31, 2025.
• Cash and cash equivalents stood at $26.7 million as of December 31, 2025, down from $41.7 million in 2024.
• Net cash used in operating activities decreased to $27.7 million in 2025 from $35.0 million in 2024.
• Research and development expenses decreased to $19.0 million in 2025 from $22.6 million in 2024, primarily due to lower manufacturing and personnel costs.
• General and administrative expenses decreased to $12.5 million in 2025 from $13.8 million in 2024.
• The VERSATILE-002 Phase 2 trial for PDS0101 + Keytruda in HPV16-positive recurrent/metastatic HNSCC showed a median overall survival (mOS) of 39.3 months for patients with CPS ≥ 1, significantly exceeding published mOS for pembrolizumab (12-18 months).
• The IMMUNOCERV Phase 2 trial for PDS0101 + chemoradiotherapy in locally advanced cervical cancer demonstrated a 36-month OS rate of 84.4% overall and 100% for patients receiving all five doses, compared to historical SOC of approximately 64%.
• The NCI-led Phase 2 trial for PDS0101 + PDS01ADC + Bintrafusp Alfa in advanced HPV-positive cancers reported 36-month survival of 75% in ICI-naive patients (vs. 7-11 months historical) and a median OS of 17 months in ICI-resistant patients (vs. 3-4 months historical).
• The company initiated the VERSATILE-003 Phase 3 clinical trial for PDS0101 + pembrolizumab in HPV16-positive first-line recurrent/metastatic HNSCC in March 2025.
• An IND application for a Phase 1 trial with PDS0103 and PDS01ADC in colorectal cancer was submitted in January 2025.
• The colorectal cancer cohort of a Phase 2 trial with PDS01ADC met criteria for expansion to stage 2 in July 2025.
• The company secured approximately $10.1 million net from a February 2025 equity offering and $4.8 million net from a November 2025 equity offering.
• In April 2025, the company issued $22.2 million in senior secured convertible debentures, using $19 million to retire previous debt, and also issued warrants to purchase 1,000,000 shares of common stock.
• A Type C meeting with the FDA was requested in October 2025 to discuss an expedited pathway for the VERSATILE-003 Phase 3 trial, with a protocol amendment to include progression-free survival (PFS) as an interim primary endpoint.
• The company received a Nasdaq deficiency letter in February 2026 for not meeting the minimum $1.00 bid price requirement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to consistently strong clinical trial data across multiple oncology programs, significantly outperforming standard-of-care benchmarks. However, the ongoing substantial net losses and the 'going concern' warning temper the overall sentiment, indicating high financial risk despite scientific promise.

Positives

• VERSATILE-002 Phase 2 trial for PDS0101 + Keytruda in HPV16-positive HNSCC showed a median overall survival (mOS) of 39.3 months for patients with CPS ≥ 1, significantly outperforming published mOS for pembrolizumab (12-18 months).
• The IMMUNOCERV Phase 2 trial for PDS0101 + chemoradiotherapy in locally advanced cervical cancer achieved a 36-month OS rate of 84.4% overall and 100% for patients receiving all five doses, substantially higher than historical SOC (approx. 64%).
• The NCI-led Phase 2 trial for PDS0101 + PDS01ADC + Bintrafusp Alfa demonstrated 36-month survival of 75% in ICI-naive patients (vs. 7-11 months historical mOS) and a median OS of 17 months in ICI-resistant patients (vs. 3-4 months historical).
• PDS01ADC monotherapy has shown activation of an immune response and correlation with clinical benefit in metastatic solid tumors, with stronger immune activation at higher doses.
• PDS01ADC in combination with docetaxel for prostate cancer resulted in decreased PSA levels in all patients, with 61% achieving at least a 60% decrease, and was well-tolerated.
• The company initiated a Phase 3 clinical trial (VERSATILE-003) for PDS0101 + pembrolizumab, indicating advancement towards potential regulatory approval.
• The colorectal cancer cohort of a Phase 2 trial with PDS01ADC met pre-defined criteria for expansion to stage 2 following positive stage 1 results.
• Preclinical data for Infectimune-based universal flu vaccine (PDS0202) demonstrated broadly protective anti-influenza immune responses and complete protection against lethal challenge with SARS-CoV-2 or influenza viruses.
• The company is actively pursuing an expedited approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer with the FDA.
• Net cash used in operating activities decreased by $7.3 million in 2025 compared to 2024, reflecting improved cash management or reduced operational burn.

Negatives

• The company has incurred significant net losses since inception, with a net loss of $34.5 million in 2025 and an accumulated deficit of $216.6 million as of December 31, 2025.
• A 'going concern' warning has been issued due to continuous net losses, negative cash flows from operations, and insufficient cash and cash equivalents to fund operations for at least 12 months.
• The company is highly dependent on additional financing, and there is no assurance that new funding will be available on acceptable terms or in required amounts.
• The company's common stock received a Nasdaq deficiency letter in February 2026 for failing to meet the minimum $1.00 bid price requirement, risking delisting.
• Interest expense increased to $4.1 million in 2025 from $2.2 million in 2024, primarily due to decreased interest income and a loss on retirement of debt.
• The senior secured convertible debentures include restrictive covenants, such as maintaining a minimum cash balance, which could limit operational flexibility.
• The ICI refractory cohort in the VERSATILE-002 trial showed 0% confirmed ORR, suggesting PDS0101's impact on survival in this group may not be dependent on tumor shrinkage, which could be a concern for broader efficacy claims.
• The company has no manufacturing, sales, marketing, or distribution capabilities and relies entirely on third parties, posing risks if these partners fail to perform.

Risks

• The company has a limited operating history and has never generated any product revenue, making predictions about future success uncertain.
• Significant losses are expected to continue for the foreseeable future, and profitability may never be achieved or maintained.
• Dependence on the success of Versamune, PDS01ADC, and Infectimune products, which are still in clinical development and may not receive regulatory approval or be successfully commercialized.
• Requirement for substantial additional capital to fund operations, with a risk of being forced to delay, reduce, or eliminate development programs if financing is not obtained.
• Raising additional funds through equity may cause dilution to existing stockholders, and debt/licensing arrangements may restrict operations or require relinquishing proprietary rights.
• Difficulties in expanding the organization and managing growth could disrupt operations.
• Risk of misconduct or improper activities by employees, contractors, and other third parties, including noncompliance with regulatory standards.
• Vulnerability to system failures or cyberattacks, which could disrupt operations, lead to data loss, or incur liability.
• Failure to maintain an effective system of internal control over financial reporting could adversely affect investor confidence and stock value.
• Increased costs and management time devoted to compliance initiatives as a public company, especially if no longer a smaller reporting company.
• Operating activities may be restricted by covenants related to outstanding indebtedness, with a risk of immediate repayment upon default.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year.
• Clinical trials are expensive, time-consuming, difficult to design, and have uncertain outcomes; failure to demonstrate safety and efficacy will prevent commercialization.
• Challenges in enrollment and retention of subjects in clinical trials, which could lead to delays or abandonment of trials.
• Significant competition from other biotechnology and biopharmaceutical companies, potentially leading to product obsolescence or market share loss.
• Reliance on third parties to conduct clinical trials and perform research/preclinical studies, with risks of unsatisfactory performance, delays, or increased costs.
• Early results from preclinical studies and early clinical trials may not be predictive of success in later-stage trials.
• Risk of expending limited resources on a particular product candidate or indication that may not be the most profitable or successful.
• Failure to comply with federal and state healthcare regulatory laws could result in criminal prosecution, substantial civil penalties, and harm to business.
• Inability to establish sales, marketing, and distribution capabilities, either independently or through collaborations, could hinder commercialization.
• Risks associated with international operations if products are commercialized outside the United States, including different regulatory requirements and reduced intellectual property protection.
• Impact of recently enacted and future healthcare legislation, regulations, and policy initiatives (e.g., ACA, IRA) on marketing approval, commercialization costs, pricing, and profitability.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Volatility in the stock price due to various factors, including clinical trial results, regulatory decisions, competition, and general market conditions.
• Risk of delisting from Nasdaq if minimum listing requirements are not met.
• Potential for increased effective tax rate due to tax legislation changes or challenges to tax positions.
• Anti-takeover provisions under Delaware law could make an acquisition more difficult.
• Global economic uncertainty, geopolitical conflicts, natural disasters, and health emergencies could adversely affect business operations and financial performance.
• Risks associated with the use of artificial intelligence, including security risks and an uncertain regulatory environment.
• Disruptions at government agencies (FDA, SEC) due to funding shortages or staffing issues could delay product development and approval.
• Adverse developments affecting the financial services industry could impair access to funding and impact liquidity.

Future Outlook

The company expects to continue incurring significant operating losses and negative cash flows for the foreseeable future as it advances its Versamune and PDS01ADC product candidates through clinical trials and seeks regulatory approvals. Future funding requirements are substantial and depend on the timing and costs of clinical trials, regulatory approvals, intellectual property protection, and potential collaborations. The company plans to finance operations through equity offerings, debt financings, and licensing arrangements, but there is no assurance that sufficient additional capital will be available on acceptable terms. The company is actively pursuing an expedited approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer and expects publication of full VERSATILE-002 results in 2026.

Management Comments

• We believe our investigational targeted immunotherapies have the potential to overcome limitations of current immunotherapy approaches through effective conversion of the immune suppressive tumor to an immunogenic microenvironment in addition to the induction of the right type, potency and quantity of tumor-targeting killer (CD8) T cells.
• We believe our proprietary combinations of Versamune and PDS01ADC together with immune checkpoint inhibitors or other standards of care, may enhance the proliferation, potency and longevity of antigen specific multifunctional CD8 T cells in the tumor microenvironment and work synergistically to inhibit or treat cancer.
• We believe our Versamune technology platform, potentially in combination with our IL-12 antibody drug conjugate, PDS01ADC, is unique in its ability to successfully encompass the mechanistic attributes required to induce a safe and effective anti-cancer immune response in preclinical data.
• We believe that the reduction of ctDNA, as a biomarker, has the potential to signify a potential reduction or elimination of cancer.
• We believe the data presented from these Phase 2 clinical trials in 2022, 2023, 2024 and 2025 demonstrated favorable results.
• We believe the key differentiating attributes of the Infectimune platform technology are strong induction of CD8 and CD4 T cells as well as antibodies which can be leveraged to improve treatment and preventive options in several infectious disease indications.
• We have concluded that substantial doubt exists about our ability to continue as a going concern within one year after the date of the filing of this Annual Report.

Industry Context

StockSavvy.ai notes that PDS Biotechnology operates in the highly competitive and rapidly evolving biotechnology and biopharmaceutical industries, characterized by intense R&D and significant capital requirements. The company's focus on T-cell activating immunotherapies and IL-12 ADCs positions it within a high-growth segment of oncology, aiming to address limitations of current checkpoint inhibitors. Its universal influenza vaccine program also targets a significant unmet need in infectious diseases. Competitors include major pharmaceutical companies like Merck, Johnson & Johnson, Sanofi-Aventis, GlaxoSmithKline, and Pfizer, as well as specialized biotech firms such as Genmab, Inovio, Moderna, and BioNTech. The company's strategy of combining its proprietary platforms with established immune checkpoint inhibitors (like Keytruda) is a common approach to enhance efficacy and differentiate in a crowded market. The pursuit of expedited regulatory pathways reflects the industry's drive to bring innovative therapies to patients faster, especially for serious conditions.

Comparison to Industry Standards

• **VERSATILE-002 (PDS0101 + Keytruda in HPV16-positive HNSCC, ICI-naive):** Median Overall Survival (mOS) of 39.3 months significantly exceeds published mOS for pembrolizumab monotherapy (12-18 months).
• **VERSATILE-002 (PDS0101 + Keytruda in HPV16-positive HNSCC, ICI-naive):** Objective Response Rate (ORR) of 36% (19/53) is higher than published ORR for pembrolizumab monotherapy (19-25%).
• **VERSATILE-002 (PDS0101 + Keytruda in HPV16-positive HNSCC, ICI-naive):** Median Progression-Free Survival (mPFS) of 10.4 months (June 2023 data) and 6.3 months (May 2024 data) significantly surpasses published mPFS of 2-3 months for approved ICIs used alone.
• **VERSATILE-002 (PDS0101 + Keytruda in HPV16-positive HNSCC):** The combination appeared well-tolerated with Grade 3-5 TRAE rates (11-13%) comparable to or lower than published rates for approved ICI monotherapy (13-17%).
• **IMMUNOCERV (PDS0101 + Chemoradiotherapy in locally advanced cervical cancer):** 36-month Overall Survival (OS) rate of 84.4% overall and 100% for patients receiving all five doses is substantially better than historical published data of approximately 64% with chemoradiation alone in this population.
• **IMMUNOCERV (PDS0101 + Chemoradiotherapy in locally advanced cervical cancer):** 36-month Progression-Free Survival (PFS) rate of 74.9% overall and 100% for patients receiving all five doses is significantly better than historical published data of approximately 61% with chemoradiation alone.
• **NCI-led Phase 2 (PDS0101 + PDS01ADC + Bintrafusp Alfa in advanced HPV-positive cancers, ICI-naive):** 75% of patients remained alive at 36 months, far exceeding published median OS of 7-11 months for similar patients.
• **NCI-led Phase 2 (PDS0101 + PDS01ADC + Bintrafusp Alfa in advanced HPV-positive cancers, ICI-resistant):** 12-month OS rate of 72% and median OS of approximately 20 months are significantly better than published median OS of 3.4 months for ICI-resistant patients.
• **NCI-led Phase 2 (PDS0101 + PDS01ADC + Bintrafusp Alfa in advanced HPV-positive cancers, ICI-naive):** Confirmed Objective Response Rate (ORR) of 75% is substantially higher than historical published results of 11-24%.

Management Changes

Corporate Governance

Legal Proceedings

• Management does not believe any pending legal proceedings or other loss contingencies will be resolved in a manner that would have a material adverse effect on the company's financial position, results of operations, or cash flows.

Related Party Transactions

• Two of the company's directors participated in the February 2025 Offering, purchasing 30,121 shares of common stock and common stock warrants to purchase 30,121 shares of common stock.

Stakeholder Impact

• **Shareholders:** Face potential dilution from ongoing equity financings and significant stock price volatility. The 'going concern' warning highlights a material risk to investment. However, strong clinical trial data offers potential for future value creation if regulatory approvals are secured.
• **Employees:** Benefit from market salaries, bonuses, equity ownership opportunities, and development programs. The company's ability to attract and retain highly skilled personnel is critical for its success.
• **Patients:** Stand to benefit from the development of potentially more effective and safer immunotherapies for various cancers (HPV-related, colorectal, prostate) and infectious diseases (universal influenza), offering improved treatment outcomes compared to current standards of care.
• **Creditors:** The company's outstanding senior secured convertible debentures are secured by substantially all assets, but the 'going concern' warning indicates elevated risk regarding the company's ability to meet future obligations without additional financing.
• **Regulatory Authorities:** The company's interactions with the FDA, including requests for expedited pathways and protocol amendments, indicate active engagement in the regulatory process, which is crucial for bringing products to market.

Next Steps

• Continue advancing VERSATILE-003 Phase 3 clinical trial for PDS0101 + pembrolizumab in HPV16-positive recurrent/metastatic HNSCC.
• Seek expedited approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer through a Type C meeting with the FDA.
• Publish full results of the VERSATILE-002 trial in 2026.
• Continue clinical and preclinical development of PDS0103 (MUC1-related cancers) and PDS01ADC.
• Advance the colorectal cancer cohort of the Phase 2 trial with PDS01ADC to stage 2.
• Continue development of Infectimune-based universal influenza vaccines (PDS0202) in alignment with NIAID's CIVICs program.
• Secure additional funding through equity offerings, debt financings, or collaborations to support ongoing operations and development programs.
• Address Nasdaq's minimum bid price requirement to avoid delisting.

Key Dates

Recommendation

The company presents compelling clinical data for its lead oncology candidates, consistently outperforming standard-of-care benchmarks in multiple Phase 2 trials. This scientific validation and the pursuit of expedited regulatory pathways are strong positives. However, the significant accumulated deficit, ongoing net losses, and the explicit 'going concern' warning from management and auditors introduce substantial financial risk. While the clinical progress suggests long-term potential, the immediate financial instability and the Nasdaq delisting notice warrant caution. A 'hold' recommendation reflects the balance between the strong clinical upside and the high financial risk, advising investors to monitor financing developments and regulatory milestones closely before making further investment decisions.

Keywords

Immunotherapy, Cancer Treatment, HPV-positive Cancers, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Colorectal Cancer, Prostate Cancer, Versamune, PDS0101, PDS01ADC, IL-12, Keytruda, Pembrolizumab, Clinical Trials, Phase 3, Oncology, Biotechnology, Infectimune, Vaccines, FDA Approval, SEC Filing, 10-K